• Cancer stem cells exhibit unique metabolic dependencies that differ from bulk tumor cells, offering therapeutic opportunities.
• Targeting glycolysis, oxidative phosphorylation, and fatty acid oxidation can selectively eliminate CSCs and overcome therapy resistance.
• Metabolic inhibitors in combination with conventional therapies show promise in preclinical studies and early clinical trials.
• Understanding the metabolic plasticity of CSCs is crucial for developing effective and durable cancer treatments.